Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Shukla SD | Platelet activating factor-stimulated formation of inositol triphosphate in platelets and its regulation by various agents including Ca2+, indomethacin, CV-3988, and forskolin. | 1985 | Arch. Biochem. Biophys. | pmid:3875314 |
Chao W et al. | Regulation of platelet-activating factor receptor and PAF receptor-mediated arachidonic acid release by protein kinase C activation in rat Kupffer cells. | 1990 | Arch. Biochem. Biophys. | pmid:2171429 |
Zhou W and Olson MS | A mechanism for phorbol ester-mediated regulation of the PAF receptor in human neutrophils. | 1994 | Arch. Biochem. Biophys. | pmid:8053680 |
Shukla SD and Hanahan DJ | Acetylglyceryl ether phosphorylcholine (AGEPC; platelet-activating factor)-induced stimulation of rabbit platelets: correlation between phosphatidic acid level, 45Ca2+ uptake, and [3H]serotonin secretion. | 1984 | Arch. Biochem. Biophys. | pmid:6465886 |
Argyroudi-Akoyunoglou JH and Vakirtzi-Lemonias C | Enhancement of chlorophyll a fluorescence yield, low-temperature F685/F730 fluorescence emission ratio, and electron transport rate by ether phospholipids (platelet activating factor and analogs) in isolated chloroplasts. | 1989 | Arch. Biochem. Biophys. | pmid:2817899 |
RodrÃguez Roisin R | [Platelet activating factor and bronchial asthma. Is it relevant?]. | 1997 | Arch. Bronconeumol. | pmid:9280556 |
Travers J et al. | Antiinflammatory activity of the platelet-activating factor receptor antagonist A-85783. | 1998 | Arch. Dermatol. Res. | pmid:9836508 |
Modschiedler K et al. | Dapsone and colchicine inhibit adhesion of neutrophilic granulocytes to epidermal sections. | 2000 | Arch. Dermatol. Res. | pmid:10664013 |
Kemény L et al. | Effect of locally applied WEB 2086, a platelet-activating factor antagonist, on inflammatory skin conditions in mice. | 1996 | Arch. Dermatol. Res. | pmid:8844132 |
Lazanas M et al. | PAF of biological fluids in disease: IV. Levels in blood in allergic reactions induced by drugs. | 1988 | Arch. Dermatol. Res. | pmid:3395143 |
Kemény L et al. | Pharmacological studies on dithranol-induced irritative dermatitis in mice. | 1989 | Arch. Dermatol. Res. | pmid:2529819 |
Judge MR et al. | Platelet activating factor (PAF) and lyso-PAF in psoriasis. | 1994 | Arch. Dermatol. Res. | pmid:7818279 |
Jørgensen KM et al. | Platelet activating factor stimulates arachidonic acid release in differentiated keratinocytes via arachidonyl non-selective phospholipase A2. | 2010 | Arch. Dermatol. Res. | pmid:20041255 |
Alappatt C et al. | Acute keratinocyte damage stimulates platelet-activating factor production. | 2000 | Arch. Dermatol. Res. | pmid:10867814 |
de Boissieu D et al. | [Study of platelet-activating factor (PAF) in stools of newborn infants with hemorrhagic colitis]. | 1991 Aug-Sep | Arch. Fr. Pediatr. | pmid:1929756 |
Morville P and Heymann M | [Regulation of perinatal pulmonary circulation]. | 1989 Jun-Jul | Arch. Fr. Pediatr. | pmid:2783008 |
Dubovsky SL et al. | Increased platelet intracellular calcium concentration in patients with bipolar affective disorders. | 1989 | Arch. Gen. Psychiatry | pmid:2735813 |
Carlioglu A et al. | The platelet activating factor acetyl hydrolase, oxidized low-density lipoprotein, paraoxonase 1 and arylesterase levels in treated and untreated patients with polycystic ovary syndrome. | 2014 | Arch. Gynecol. Obstet. | pmid:24840107 |
Hruby ZW et al. | Mechanisms of glomerular injury in experimental immune nephritis. II. Effect of a platelet activating factor receptor antagonist in an autologous nephritis model. | 1991 | Arch. Immunol. Ther. Exp. (Warsz.) | pmid:1668710 |
Wysocki H | The role of polymorphonuclear neutrophils in myocardial damage during ischemia and reperfusion. | 1992 | Arch. Immunol. Ther. Exp. (Warsz.) | pmid:1485826 |
Rosenbaum JT et al. | Synthesis of platelet activating factor by ocular tissue from inflamed eyes. | 1991 | Arch. Ophthalmol. | pmid:2003804 |
Rubin RM et al. | Prostaglandin-independent inhibition of ocular vascular permeability by a platelet-activating factor antagonist. | 1988 | Arch. Ophthalmol. | pmid:3261165 |
Noguchi K et al. | The detection of platelet-activating factor in inflamed human gingival tissue. | 1989 | Arch. Oral Biol. | pmid:2783040 |
Hirafuji M and Shinoda H | Increased prostaglandin I2 and thromboxane A2 production by rat dental pulp after intravenous administration of endotoxin. | 1994 | Arch. Oral Biol. | pmid:7695514 |
Krause S et al. | Aggregation behaviour of blood granulocytes in patients with periodontal disease. | 1990 | Arch. Oral Biol. | pmid:2390026 |
Nohutcu RM et al. | Effects of hormones and cytokines on stimulation of adenylate cyclase and intracellular calcium concentration in human and canine periodontal-ligament fibroblasts. | 1993 | Arch. Oral Biol. | pmid:7506523 |
Mann EA et al. | Phospholipid metabolite expression by head and neck squamous cell carcinoma. | 1994 | Arch. Otolaryngol. Head Neck Surg. | pmid:8018329 |
Rehse K et al. | New 1H-pyrazole-4-carboxamides with antiplatelet activity. | 2009 | Arch. Pharm. (Weinheim) | pmid:19051198 |
Disselnkötter H et al. | [Synthesis of phosphono analogs of 2-O-acetyl-1-O-hexadecyl(octadecyl)-sn-3-glycerylphosphorylcholine (platelet-activating factor)]. | 1985 | Arch. Pharm. (Weinheim) | pmid:4051690 |
Xu LF et al. | Disruption of the F-actin cytoskeleton and monolayer barrier integrity induced by PAF and the protective effect of ITF on intestinal epithelium. | 2011 | Arch. Pharm. Res. | pmid:21380808 |
Huh H et al. | PAF antagonistic activity of 2-hydroxy-3-methoxybenzoic acid glucose ester from Gentiana scabra. | 1998 | Arch. Pharm. Res. | pmid:9875472 |
Grypioti AD et al. | Platelet-activating factor (PAF) involvement in acetaminophen-induced liver toxicity and regeneration. | 2005 | Arch. Toxicol. | pmid:15995853 |
Massicot F et al. | Inhibitory effects of a platelet activating factor-antagonist 48740RP in cyclosporin-induced nephrotoxicity in the rat as assessed by renal glutathione metabolism parameters. | 1991 | Arch. Toxicol. Suppl. | pmid:1687197 |
Misawa M and Sugiyama Y | An airway hyperresponsiveness model in rat allergic asthma. | 1993 | Arerugi | pmid:8507151 |
Tsukioka K et al. | [Increased plasma levels of platelet-activating factor (PAF) and low serum PAF acetylhydrolase (PAFAH) activity in adult patients with bronchial asthma]. | 1993 | Arerugi | pmid:8507159 |
Kakazu T et al. | [Effect of platelet-activating factor (PAF) on eosinophil adhesion to plasma-coated glass using eosinophilic cell lines (EoL-1, EoL-3)]. | 1994 | Arerugi | pmid:8031255 |
Kawata E et al. | Effect of benzodiazepine on antigen-induced eosinophil infiltration into guinea pig conjunctiva. | 1996 | Arerugi | pmid:8752723 |
Arima M et al. | [Platelet activating factor (PAF)-induced late asthmatic response in sensitized but not in non-sensitized guinea pigs]. | 1992 | Arerugi | pmid:1520069 |
Hashimoto T et al. | [Effect of tazanolast on platelet activating factor-induced airway hyperresponsiveness in guinea pigs]. | 1992 | Arerugi | pmid:1280089 |
Ganbo T et al. | [The inhibitory effects of platelet activating factor (PAF) on ciliary activity of human paranasal sinus mucosa]. | 1992 | Arerugi | pmid:1482297 |
Tomooka M et al. | [Azelastine inhibits bronchoconstriction induced by histamine and leukotriene C4]. | 1988 | Arerugi | pmid:2906534 |
Makino S | [Platelet activating factor in allergic reaction]. | 1988 | Arerugi | pmid:3052368 |
Nakahodo K et al. | Histamine release from rabbit platelets by platelet-activating factor (PAF). | 1994 | Arerugi | pmid:7515227 |
Akagi M et al. | Contribution of platelet activating factor (PAF) in histamine-induced model of nasal allergy in rats. | 1995 | Arerugi | pmid:7646374 |
Arima M et al. | [Involvement of platelet activating factor (PAF) in ovalbumin antigen-induced late asthmatic response and increase of airway hyperresponsiveness in a guinea pig experimental model of asthma]. | 1991 | Arerugi | pmid:2069513 |
Kobayashi Y et al. | [Inhibitory effect of suplatast tosilate on eosinophil migration]. | 2000 | Arerugi | pmid:10944827 |
Imai T et al. | [The role of thromboxane A2 in the development of airway responsiveness after platelet activating factor inhalation in dogs]. | 1991 | Arerugi | pmid:2029218 |
Fukuda T et al. | [Antigen-induced biphasic eosinophil infiltration in the airways of actively sensitized guinea pigs and its inhibition by PAF antagonist and cyclosporin A]. | 1990 | Arerugi | pmid:2222197 |
Nakamura T et al. | [Platelet-activating factor in Japanese cedar pollinosis]. | 1990 | Arerugi | pmid:2222198 |
Imai T et al. | [Relation of platelet activating factor induced airway hyperresponsiveness to thromboxane A2 and neutrophil in dogs]. | 1993 | Arerugi | pmid:8250720 |
Imai T et al. | [The role of 5-lipoxygenase products in the development of airway responsiveness induced by platelet activating factor inhalation in dogs]. | 1991 | Arerugi | pmid:1854258 |
Arima M et al. | [Effect of BAY u3405-thromboxane A2 receptor antagonist, on biphasic airway responses induced by platelet-activating factor in actively sensitized guinea pigs]. | 1995 | Arerugi | pmid:7575136 |
Ichikawa Y et al. | [Effect of glycyrrhizin on the production of platelet-activating factor from rat peritoneal exudate cells]. | 1989 | Arerugi | pmid:2783037 |
de Almeida PJ and Pires JG | [Antiplatelet agents: specific agonist inhibitors]. | 1989 | Arq. Bras. Cardiol. | pmid:2575895 |
de Almeida PJ et al. | [Biochemical bases of platelet activity in homeostasis and thrombogenesis. III]. | 1987 | Arq. Bras. Cardiol. | pmid:3328601 |
Dentan C et al. | PAF-acether-degrading acetylhydrolase in plasma LDL is inactivated by copper- and cell-mediated oxidation. | 1994 | Arterioscler. Thromb. | pmid:8123638 |
Mori TA et al. | Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease. | 1997 | Arterioscler. Thromb. Vasc. Biol. | pmid:9081682 |
D'Andrea D et al. | Induction of tissue factor in the arterial wall during recurrent thrombus formation. | 2003 | Arterioscler. Thromb. Vasc. Biol. | pmid:12869352 |
Tselepis AD et al. | PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. | 1995 | Arterioscler. Thromb. Vasc. Biol. | pmid:7583554 |
Tsoukatos DC et al. | Copper-catalyzed oxidation mediates PAF formation in human LDL subspecies. Protective role of PAF:acetylhydrolase in dense LDL. | 1997 | Arterioscler. Thromb. Vasc. Biol. | pmid:9437199 |
Montrucchio G et al. | Platelet-activating factor enhances vascular endothelial growth factor-induced endothelial cell motility and neoangiogenesis in a murine matrigel model. | 2000 | Arterioscler. Thromb. Vasc. Biol. | pmid:10634803 |
Tsimikas S et al. | New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. | 2007 | Arterioscler. Thromb. Vasc. Biol. | pmid:17626905 |
Stengel D et al. | Expression of the PAF receptor in human monocyte-derived macrophages is downregulated by oxidized LDL: relevance to the inflammatory phase of atherogenesis. | 1997 | Arterioscler. Thromb. Vasc. Biol. | pmid:9157961 |
Frostegård J et al. | Platelet-activating factor and oxidized LDL induce immune activation by a common mechanism. | 1997 | Arterioscler. Thromb. Vasc. Biol. | pmid:9157962 |
Kimura M et al. | Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. | 1997 | Arterioscler. Thromb. Vasc. Biol. | pmid:9301630 |
De Geest B et al. | Effect of overexpression of human apo A-I in C57BL/6 and C57BL/6 apo E-deficient mice on 2 lipoprotein-associated enzymes, platelet-activating factor acetylhydrolase and paraoxonase. Comparison of adenovirus-mediated human apo A-I gene transfer and human apo A-I transgenesis. | 2000 | Arterioscler. Thromb. Vasc. Biol. | pmid:11031226 |
Li N et al. | Platelet-leukocyte cross talk in whole blood. | 2000 | Arterioscler. Thromb. Vasc. Biol. | pmid:11116075 |
Calabresi L et al. | Endothelial protection by high-density lipoproteins: from bench to bedside. | 2003 | Arterioscler. Thromb. Vasc. Biol. | pmid:12969988 |
Nilsson J et al. | Lipoprotein-like phospholipid particles inhibit the smooth muscle cell cytotoxicity of lysophosphatidylcholine and platelet-activating factor. | 1998 | Arterioscler. Thromb. Vasc. Biol. | pmid:9445250 |
Ilveskero S et al. | Procoagulant activity on platelets adhered to collagen or plasma clot. | 2001 | Arterioscler. Thromb. Vasc. Biol. | pmid:11304482 |
Whatley RE et al. | Endothelium from diverse vascular sources synthesizes platelet-activating factor. | 1988 May-Jun | Arteriosclerosis | pmid:3130833 |
Rouis M et al. | Expression of elastase activity by human monocyte-macrophages is modulated by cellular cholesterol content, inflammatory mediators, and phorbol myristate acetate. | 1990 Mar-Apr | Arteriosclerosis | pmid:2317158 |
Kirchmaier CM et al. | A platelet stimulating fraction in human and animal tissues. | 1980 | Artery | pmid:6971084 |
Sperling RI et al. | Inhibition of leukotriene B4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate. | 1990 | Arthritis Rheum. | pmid:2167685 |
Sperling RI et al. | Effects of dietary supplementation with marine fish oil on leukocyte lipid mediator generation and function in rheumatoid arthritis. | 1987 | Arthritis Rheum. | pmid:3663263 |
Chatham WW et al. | Ligand-dependent release of active neutrophil collagenase. | 1990 | Arthritis Rheum. | pmid:2154997 |
Tselepis AD et al. | Association of the inflammatory state in active juvenile rheumatoid arthritis with hypo-high-density lipoproteinemia and reduced lipoprotein-associated platelet-activating factor acetylhydrolase activity. | 1999 | Arthritis Rheum. | pmid:10025933 |
Kowanko IC et al. | Platelet-activating factor inhibits proteoglycan synthesis and enhances neutrophil-mediated proteoglycan degradation in cartilage explants. | 1992 | Arthritis Rheum. | pmid:1322671 |
Simoni J et al. | Cytokines and PAF release from human monocytes and macrophages: effect of hemoglobin and contaminants. | 1994 | Artif Cells Blood Substit Immobil Biotechnol | pmid:7994374 |
Edwards CM et al. | Effects of the co-polymer surfactant, Pluronic F-68, on platelet aggregation in human whole blood. | 1997 | Artif Cells Blood Substit Immobil Biotechnol | pmid:9285052 |
Wratten ML et al. | Hemolipodialysis attenuates oxidative stress and removes hydrophobic toxins. | 2000 | Artif Organs | pmid:11012537 |
Muacevic G and Heuer HO | Platelet-activating factor antagonists in experimental shock. | 1992 | Arzneimittelforschung | pmid:1418068 |
Imanishi N et al. | Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride. | 1994 | Arzneimittelforschung | pmid:8192697 |
Asaka N et al. | Effects of the new benzimidazole derivative TAS-203, an orally active phosphodiesterase 4 inhibitor, on airway inflammation in rats and emetic responses in ferrets. | 2010 | Arzneimittelforschung | pmid:21117500 |
Brecht HM et al. | Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man. | 1991 | Arzneimittelforschung | pmid:1646613 |
Berti F et al. | New pharmacological data on the bronchospasmolytic activity of bamifylline. | 1988 | Arzneimittelforschung | pmid:3365275 |
Natsume Y et al. | Effect of the platelet activating factor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride on endotoxin-induced hypotension and hematological parameters in rats. | 1994 | Arzneimittelforschung | pmid:7848333 |
Houlihan WJ et al. | Antitumor activity of a piperidine phospholipid. | 1994 | Arzneimittelforschung | pmid:7848363 |
Giudice A et al. | Prevention of platelet-activating factor-induced gastrointestinal lesions in rats by the new specific antagonist N-(2-dimethylaminoethyl)-N-(3-pyridinylmethyl)[4-(2,4,6-triisopropylphe nyl) thiazol-2yl]amine. | 1996 | Arzneimittelforschung | pmid:8740089 |
Tsunoda H et al. | Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist. | 1990 | Arzneimittelforschung | pmid:2085331 |
Cheung HT et al. | Inhibition of platelet aggregation by diterpene acids from Pinus massoniana resin. | 1994 | Arzneimittelforschung | pmid:8135873 |
Tasaka K et al. | Anti-platelet activating factor, anti-leukotriene D4 and some other antiallergic activities of mequitazine. | 1990 | Arzneimittelforschung | pmid:1705425 |
Manzini S et al. | Pharmacodynamic profile of isbufylline, a new antibronchospastic xanthine devoid of central excitatory actions. | 1990 | Arzneimittelforschung | pmid:1707621 |
Ohmori K et al. | Antiinflammatory and antiallergic effects of a novel metabolite of Nocardiopsis sp. as a potent protein kinase C inhibitor from microbial origin. | 1988 | Arzneimittelforschung | pmid:2972291 |
Tasaka K et al. | Inhibitory effect of epinastine on bronchoconstriction induced by histamine, platelet activating factor and serotonin in guinea pigs and rats. | 1994 | Arzneimittelforschung | pmid:7910745 |
Sakuma Y et al. | Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist. Effects on microvascular permeability, hypotension and nephrosis. | 1991 | Arzneimittelforschung | pmid:1815526 |
Tanaka T et al. | Effect of a novel xanthine derivative on experimental ulcers in rats. | 1993 | Arzneimittelforschung | pmid:8329000 |
Evangelista S et al. | Pharmacodynamic profile of the new potent antibronchospastic agent 7-[(2,2-dimethyl)propyl]-1-methyl xanthine. | 1995 | Arzneimittelforschung | pmid:7612055 |
Akagi M et al. | Inhibitor effect of apafant on bronchopulmonary responses to platelet activating factor and to antigen in rats. | 1997 | Arzneimittelforschung | pmid:9450165 |
Kapui Z et al. | Experimental studies on guanosine 3',5'-cyclic monophosphate levels and airway responsiveness of the novel phosphodiesterase type 5 inhibitor SR 265579 in guinea-pigs. | 1999 | Arzneimittelforschung | pmid:10483515 |